Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap201.82M
Enterprise Value162.81M
STRO
(NASDAQ)Sutro Biopharma, Inc.
$23.78-- (--)
Loading... - Market loading
Sutro Biopharma (STRO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)2.00
Forward Price/Sales2.85
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue1.54
EV/Earnings-0.75
EV/EBITDA-0.98
EV/EBIT-0.94
EV/FCF-0.72
Stock Price
Current price, 52-week range, and moving averages
Current Price$23.78
1-Day Change-0.16%
52-Week High$26.54
52-Week Low$5.23
52-Week Change317.77%
YTD Change126.92%
1-Year Change294.51%
50-Day MA$19.63
200-Day MA$11.79
Avg Volume (30 day)126.29K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding8.49M
Book Value per Share$-10.28
Net Cash per Share$6.83
FCF per Share$-26.52
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$33.25
Target Upside/Downside39.82%
Analyst ConsensusBuy
Analyst Count4
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin100.00%
EBITDA Margin (ttm)-157.54%
EBIT Margin (ttm)-164.70%
Operating Margin (ttm)-129.26%
Pretax Margin (ttm)-202.97%
Profit Margin (ttm)-205.18%
FCF Margin (ttm)-213.08%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Assets (ttm)-103.39%
Return on Capital Employed (ttm)-126.30%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue105.65M
Gross Profit105.65M
Operating Income-136.55M
Pretax Income-214.43M
Net Income-216.77M
EBITDA-166.43M
EBIT-174.00M
Diluted EPS$-25.54
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-222.53M
Capital Expenditures2.58M
Free Cash Flow-225.11M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)209.66M
Cash & Securities (mrq)65.93M
Net Cash (mrq)57.97M
Net Cash per Share$6.83
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)17.66M
Working Capital (mrq)110.22M
Total Equity (mrq)-87.27M
Book Value per Share$-10.28
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.53
Quick Ratio (mrq)2.53
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-102.70%
FCF Yield-106.65%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-7.40
Piotroski F-Score2/9
Frequently Asked Questions About Sutro Biopharma Statistics
What are the key financial metrics for STRO?
Sutro Biopharma, Inc. (STRO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is STRO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Sutro Biopharma is overvalued or undervalued.
How do I read STRO's profitability ratios?
Sutro Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do STRO's debt ratios indicate?
The financial health section shows Sutro Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is STRO's dividend analysis?
The dividend section covers Sutro Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.